Abstract
Fu et al investigated human adipose-derived mesenchymal stem cell exosomes for androgenetic alopecia, identifying a stable set of 232 proteins and proposing the CDC42-Wnt/β-catenin- glycogen synthase kinase 3β signaling axis. These findings support the potential for clinical translation. To further strengthen clinical relevance, we recommend: (1) More comprehensive exosome characterization, including key marker analysis; (2) Reporting both particle count and protein concentration, and establishing dose-response relationships; (3) Direct validation of CDC42's role through knockout or overexpression experiments; (4) Multi-level evaluation of Wnt/β-catenin signaling; (5) Enhanced biochemical validation in animal models; (6) Quantitative analysis of microneedle delivery parameters and retention; and (7) Early development of a streamlined quality control and safety framework. These methodological advancements will help exosome-based therapies better align with emerging regulatory standards and clinical guidelines. By addressing these aspects, future research can facilitate the safe, effective, and reproducible application of exosome-based treatments in clinical practice.